MicroRNA-26a alleviates tubulointerstitial fibrosis in diabetic kidney disease by targeting PAR4

Area of Science:

• Nephrology
• Molecular Biology
• Biochemistry

Background:

• Diabetic kidney disease (DKD) is a major cause of chronic kidney disease.
• Tubulointerstitial fibrosis (TIF) is a key pathological feature of DKD progression.
• The role of microRNA-26a (miR-26a) in DKD-associated TIF is not well understood.

Purpose of the Study:

• To investigate the role and mechanism of miR-26a in TIF in DKD models.
• To explore the potential of exogenous miR-26a as a therapeutic agent for DKD.

Main Methods:

• Quantitative real-time PCR (RT-qPCR) to measure miR-26a levels in db/db mice and high glucose-stimulated mouse tubular epithelial cells (mTECs).
• In vivo and in vitro overexpression of miR-26a using adeno-associated virus and adenovirus vectors.
• Assessment of TIF and extracellular matrix (ECM) deposition.
• Analysis of protease-activated receptor 4 (PAR4) expression and its role in miR-26a's anti-fibrotic effects.

Main Results:

• miR-26a expression was significantly decreased in DKD models (db/db mice and high glucose-treated mTECs).
• Overexpression of miR-26a attenuated TIF and ECM deposition in db/db mice and mTECs, respectively.
• miR-26a exerted its protective effects by downregulating PAR4 expression.
• Restoring PAR4 expression reversed the anti-fibrotic effects of miR-26a.

Conclusions:

• miR-26a plays a protective role against TIF in DKD.
• miR-26a alleviates TIF in DKD by directly targeting and inhibiting PAR4.
• Targeting the miR-26a/PAR4 axis presents a promising therapeutic strategy for DKD.